Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib (Q40240678)
Jump to navigation
Jump to search
scientific article published on August 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib |
scientific article published on August 2006 |
Statements
1 reference
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib (English)
1 reference
Marcus Wiedmann
1 reference
Jürgen Feisthammel
1 reference
Thilo Blüthner
1 reference
Andrea Tannapfel
1 reference
Thomas Kamenz
1 reference
Annett Kluge
1 reference
Joachim Mössner
1 reference
Karel Caca
1 reference
1 August 2006
1 reference
1 reference
17
1 reference
7
1 reference
783-795
1 reference
Identifiers
1 reference
1 reference